Macular degeneration. Advances in treatment.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000975:Antioxidants / Q000627:therapeutic use; D052157:Aptamers, Nucleotide / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008028:Light Coagulation / Q000379:methods; D008268:Macular Degeneration / Q000145:classification / Q000517:prevention & control / Q000628:therapy*; D010778:Photochemotherapy / Q000379:methods; D011244:Pregnadienediols; D000069579:Ranibizumab; D014221:Triamcinolone / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000975:Antioxidants; D052157:Aptamers, Nucleotide; D005938:Glucocorticoids; D011244:Pregnadienediols; D014221:Triamcinolone; C495058:pegaptanib; C418047:anecortave acetate; D000069579:Ranibizumab